Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ROTIGOTINE

All products: Limited Use (codes 510)

Neupro · DIN 02403943 · 8mg/24hr · Trans Patch

Limited Use — Reason for Use code 510 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 510 required
Write on scriptLU code 510 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 510
Reason for Use code 510 For adjunctive therapy to levodopa for the treatment of patients with advanced stage Parkinson's disease (APD). Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Neupro · DIN 02403943 Manufacturer: UCB Canada Inc.; listing date 2017-09-28 Health Canada: Marketed since 2013-06-27 · brand NEUPRO · ATC N04BC09 ROTIGOTINE · form Patch · route Transdermal · ingredients ROTIGOTINE 8 MG/24HOUR · company Ucb canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Neupro: Formulary list price $7.8620/unit (unit not stated in source; not the patient's cost)

Ministry pays: $7.8620 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88871 · Verify on the e-Formulary ↗ (DIN 02403943)

Source record
DIN 02403943: Neupro Raw flags: sec12=Y, sec3=Y Item: 283620004; group id 532; item number 1441; lccId 00290; manufacturer id UCB Source form: Trans Patch; strength: 8mg/24hr Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $7.8620; ministry $7.8620 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02403943 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88871
Shortage status: resolved shortage (ended 2024-04-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02403943
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:36:20 Dopamine Receptor Agonists) and how they are covered
No products matched this class search: “28:36:20”. This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code. Search this as a medication name or DIN
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications NEUPRO (rotigotine) is indicated in adults (≥18 year of age) for: • The treatment of the signs and symptoms of idiopathic Parkinson’s disease. NEUPRO may be used both as early therapy, without concomitant levodopa, and as an adjunct to levodopa. • The symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) 1.1. Pediatrics The safety and efficacy of NEUPRO have not been studied in children less than 18 years of age, therefore NEUPRO is not recommended in this patient population (see 7 Warnings and Precautions, Special Populations, Pediatrics). 1.2. Geriatrics Patients above the age of 65 were included in the clinical trials for NEUPRO. NEUPRO dosing can be titrated in the normal manner but may be individualized to accommodate advanced age and potential age-related comorbidity. https://pdf.hres.ca/dpd_pm/00083389.PDF PM date: 2026-02-02 Source product: NEUPRO; DIN 02403900; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.